Format

Send to

Choose Destination
Clin Pharmacol Ther. 2013 Apr;93(4):335-41. doi: 10.1038/clpt.2013.1. Epub 2013 Jan 15.

Computational drug repositioning: from data to therapeutics.

Author information

1
Computational Biology, GlaxoSmithKline R&D, King of Prussia, Pennsylvania, USA.

Abstract

Traditionally, most drugs have been discovered using phenotypic or target-based screens. Subsequently, their indications are often expanded on the basis of clinical observations, providing additional benefit to patients. This review highlights computational techniques for systematic analysis of transcriptomics (Connectivity Map, CMap), side effects, and genetics (genome-wide association study, GWAS) data to generate new hypotheses for additional indications. We also discuss data domains such as electronic health records (EHRs) and phenotypic screening that we consider promising for novel computational repositioning methods.

PMID:
23443757
DOI:
10.1038/clpt.2013.1
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center